Screener
Maze Therapeutics MAZE Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -37.3%— | -38.7%— | —— | —— | —— | |
| Return on invested capital | -87.3%— | -117.8%— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 18.3×+4.7× | 17.9×+1.8× | 15.5×+5.7× | 17.7×— | 13.6×— | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.2×+0.1× | 0.1×— | 0.1×— | 0.1×— | |
| Per Share | ||||||
| Book value per share | $7.68+28.3% | $6.34-37.9% | $8.26+107% | $8.29— | $5.99— | |
| Valuation | ||||||
| Market capitalization | $1.51B+156% | $1.47B— | $1.99B— | $1.14B— | $452.42M— | |
| Price / book | 3.3×+1.1× | 4.3×— | 5.6×— | 3×— | 1.7×— |
FAQ
- Where do Maze Therapeutics's ratios come from?
- Every ratio is computed from Maze Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.